The deal is "an important commercial step" for Limaca to push through a wider clinical rollout of Precision-GI, says Trendlines.
The company describes Precision-GI as biopsy system used to collect intact, high-quality core tissue from pancreatic and other gastrointestinal lesions while minimising blood contamination.
Pancreatic and other gastrointestinal cancers continue to rank among the deadliest globally, with a significant proportion of patients diagnosed at advanced stages.
"Achieving a definitive diagnosis on the initial procedure is essential for prompt and effective treatment," reads the Trendlines announcement on Jan 4.
See also: UltraGreen.ai not in a hurry to list despite 65 Equity Partners’ investment
“This agreement endorses the validation of the quality and commercial potential within the Trendlines portfolio,” says Haim Brosh, CEO of Trendlines.
“We are proud to support companies that not only deliver innovation but also create meaningful impact in healthcare.”
Trendlines Group shares closed at 7.4 cents on Jan 2, up 1.37% for the day and up 48% in the past 12 months.
